TrialNature medicine2023

Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial.

Manish A Shah et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.